Longeveron's Innovative Presentation at CTAD24
MIAMI, Oct. 14, 2024 - Longeveron Inc., a prominent clinical-stage biotechnology firm dedicated to regenerative medicines, has made an exciting announcement regarding its Lomecel-B breakthrough in Alzheimer's research. The company revealed that its recent submission, titled "Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer's disease," will be featured in a late-breaking poster presentation at the prestigious Clinical Trials on Alzheimer's Disease Conference (CTAD24), scheduled for the end of October 2024.
Excitement Around Lomecel-B Findings
According to Wa'el Hashad, CEO of Longeveron, the selection of their research underscores the importance of their findings in understanding Lomecel-B’s potential roles in Alzheimer's treatment. He expressed enthusiasm for sharing insights that could lead to innovative cellular therapies aimed at tackling this complex disease. The importance of presenting at CTAD—a leading venue for Alzheimer's research—adds significant credibility to their ongoing efforts.
Details of the Late-Breaking Poster
Key Presentation Insights
The detailed poster presentation is set to occur on Tuesday, October 29, 2024, between 3:00 p.m. CEST and 5:00 p.m. CEST on the following day. This year's conference theme focuses on 'New Therapies and Clinical Trials,' positioning it perfectly for Longeveron’s innovative approach.
Poster Title and Insights
The official title of the presentation will be "LP029 Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer's." This title signifies Longeveron's commitment to uncovering the mechanistic underpinnings of its therapeutic products, particularly in their application for Alzheimer's disease.
The Importance of the Abstract
The abstract of this pivotal poster will also be published in the special CTAD edition of the Journal of Prevention of Alzheimer's Disease (JPAD), the official journal for the conference. This inclusion not only strengthens the findings but also aids in disseminating valuable research to a broader audience interested in Alzheimer's advancements.
Understanding Lomecel-B™
Lomecel-B™ is a living cell therapy extracted from specialized cells found in the bone marrow of young, healthy donors. These cells, termed medicinal signaling cells (MSCs), are integral to the body's natural repair mechanisms. They perform various roles, including tissue formation and responding to instances of injury, thereby releasing bioactive factors which bolster regeneration and modulate immune responses. With its multifactorial action pathways, Lomecel-B™ represents a burgeoning possibility for treating aging-related diseases and inflammation-related conditions.
Longeveron’s Mission and Pipeline
Longeveron Inc. is on a path to reshape treatment paradigms in regenerative medicine, targeting unfulfilled medical needs. At the helm of its efforts is Lomecel-B™, which exhibits several beneficial potential mechanisms, such as promoting vascular health, enhancing tissue repair, and combatting inflammation. Currently, Longeveron is advancing three key indications: hypoplastic left heart syndrome, Alzheimer's disease, and aging-related frailty. Their significant clinical development has received multiple U.S. FDA designations, emphasizing their innovative approach to therapy development.
Investment and Contact Information
For inquiries related to investment or media, contact Derek Cole at Investor Relations Advisory Solutions, available through email. Interested parties can also keep up with Longeveron’s latest developments on their official website, as well as through their social media platforms on LinkedIn, X, and Instagram.
Frequently Asked Questions
What is Lomecel-B?
Lomecel-B is a living cell product derived from specialized bone marrow cells that have demonstrated potential therapeutic effects in treating various diseases.
Where will Longeveron present its research?
Longeveron’s research will be presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24).
What is the significance of CTAD24?
CTAD24 is a major conference focused on advancements in Alzheimer's research, highlighting new therapies and clinical trials.
What is the focus of Longeveron's research?
Longeveron is focused on using regenerative medicine to address unmet medical needs in Alzheimer's disease and other age-related conditions.
How can I learn more about Longeveron?
For more information, visit Longeveron’s official website and follow their social media channels for updates and news.
